PD L1 News and Research

RSS

Immunotherapy drug shows favorable safety profile in patients with advanced small cell lung cancer

The immunotherapy drug pembrolizumab has demonstrated a favorable safety profile and "promising durable clinical activity" in pretreated patients who exhibit high levels of the PD-L1 protein in advanced stages of small cell lung cancer (SCLC) – an aggressive form of the disease

16 Aug 2017

DKFZ scientists reveal how cancer cells suppress immune system to spread and multiply

The degenerated cells cause an inflammatory reaction and influence other blood cells with it so much, that the immune system is suppressed.

28 Jul 2017

Study: Response to combination immunotherapy in melanoma depends on proportion of immune cells

Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco researchers joined by physicians from UCSF Health.

20 Jul 2017

Scientists develop potential new therapy for targeting skin cancer metastases in the brain

Investigators from Brigham and Women's Hospital (BWH) and the Harvard Stem Cell Institute have a potential solution for how to kill tumor cells that have metastasized to the brain.

10 Jul 2017

Scientists create 'immunoswitch' particles that slow cancer growth in test animals

Scientists at Johns Hopkins have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells' defensive properties while switching on a robust anticancer immune response in mice.

8 Jun 2017

Researchers find new way to improve T-cell therapy for treating cancer

Scientists have armed immune cells with a new surface molecule. This causes the cells to respond particularly aggressively when they encounter a protein that tumors actually use to camouflage themselves from the immune system.

8 Jun 2017

Two-pronged algorithm may prove to be accurate tool for predicting response to checkpoint inhibitors

The class of immunotherapies known as checkpoint inhibitors have proven to be a highly effective and advantageous treatment option for many cancer patients, but they don't work well for everyone, and oncologists have no reliable way to determine in advance which patients are likely to respond to these drugs.

7 Jun 2017

Novel vaccine therapy can generate immune responses in patients with HPV-related head and neck cancer

A novel vaccine therapy can generate immune responses in patients with head and neck squamous cell carcinoma (HNSCCa), according to researchers at the Abramson Cancer Center of the University of Pennsylvania.

31 May 2017

FDA grants accelerated approval to cancer treatment based on common biomarker

The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).

23 May 2017

Study findings could lead to quick and new way for predicting efficacy of cancer treatments

Once hailed as a breakthrough in cancer treatment, immunotherapies are now raising concerns as doctors note new side effects like severe allergic reactions, acute-onset diabetes and heart damage.

23 May 2017

Researchers show how cancer therapy works in different way to destroy tumor cells

Antibodies to the proteins PD-1 and PD-L1 have been shown to fight cancer by unleashing the body's T cells, a type of immune cell.

18 May 2017

Recurrence of HPV-negative HNSCC after radiation therapy linked to high tumor levels of PD-L1 protein

Recurrence of head and neck squamous cell carcinoma (HNSCC) negative for human papillomavirus (HPV) following radiation therapy was associated with high tumor levels of the protein PD-L1.

5 May 2017

New research identifies immunotherapy targets to offer hope for early-stage lung cancer patients

Immunotherapy, which has achieved remarkable results in late-stage lung cancer patients, can also hold great hope for newly diagnosed patients, cutting the deadly disease off before it has the chance to take hold and offering a potential cure, according to a new Mount Sinai study published today in Cell.

4 May 2017

Study suggests how existing and emerging immunotherapy treatments could be successful for sarcomas

Sarcomas- cancers of the connective tissues like muscles, joints, fat and bone - come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers.

3 May 2017

Researchers find new way to prevent graft-versus-host disease after stem cell transplants

Through experimental work, an international team of researchers led by City of Hope's Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation, believe they may have found a way to prevent graft-versus-host disease after stem cell transplants while retaining the transplants' positive effects on fighting leukemia and lymphoma.

18 Apr 2017

Combination of anti-angiogenic and immune-stimulating therapies can lead to effective cancer treatments

Scientists from VIB and KU Leuven, together with colleagues from the University of California and the Swiss Institute for Experimental Cancer Research have demonstrated that, anti-angiogenic therapy can improve immune boosting treatments.

13 Apr 2017

ANGLE's Parsortix system shows high sensitivity, purity in gene expression analysis of head and neck cancers

ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE’s Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.

4 Apr 2017

Patients' immune system profiles could be linked to effectiveness of cancer immunotherapy

Higher or lower levels of certain immune cells in cancer patients may be associated with how well they respond to immunotherapy, according to preliminary results of a study conducted by researchers at the University of Pittsburgh Cancer Institute.

3 Apr 2017

Study explores new immunotherapy combinations to treat prostate cancer

Prostate cancer, notoriously resistant to immunotherapy due to its immunologically cool nature, triggers two pathways to chill an immune attack after one immunotherapy drug fires up the immune system, researchers at The University of Texas MD Anderson Cancer Center report in Nature Medicine.

29 Mar 2017

FDA grants accelerated approval to new drug for treatment of rare form of skin cancer

The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.

23 Mar 2017